ASCO 2021 | Larotrectinib in adult and pediatric patients with TRK fusion-positive primary CNS tumors
Sébastien Perreault, MD, FRCPC, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada, outlines efficacy and safety data of larotrectinib, a first-in-class, highly selective TRK inhibitor in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumors. In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Sébastien Perreault, MD, FRCPC has received an advisory board role and conference support from Bayer, conference support from Eisai, and research support from Novartis.
